Onkologisches Zentrum Wolfsburg-Helmstedt MVZ GmbH
- Address
- Kaufhofpassage 5-7, Innenstadt, 38440 Wolfsburg, Germany
Onkologisches Zentrum Wolfsburg-Helmstedt MVZ GmbH
The Onkologisches Zentrum Wolfsburg-Helmstedt MVZ GmbH is a specialized oncology center dedicated to advancing cancer treatment through participation in innovative clinical research. The center demonstrates expertise in hematologic malignancies, with a particular focus on optimizing therapeutic approaches that balance efficacy with patient safety and quality of life.
- Advanced stage Hodgkin lymphoma treatment protocols
- Novel chemotherapy regimen development and evaluation
- PET-guided radiation therapy strategies
The center's research portfolio emphasizes the development of reduced-toxicity treatment regimens for complex hematological cancers. Their involvement in comparative effectiveness studies evaluating BrECADD versus escalated BEACOPP protocols reflects a commitment to identifying therapeutic approaches that minimize treatment-related morbidity while maintaining superior progression-free survival outcomes. This focus on precision oncology and personalized treatment strategies positions the center at the forefront of modern lymphoma care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Onkologisches Zentrum Wolfsburg-Helmstedt MVZ GmbH
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of BrECADD Versus Escalated BEACOPP in First-Line Treatment of Advanced Hodgkin Lymphoma: A Randomized Controlled Trial | University Of Cologne | Phase III | Not Recruiting | Jul 2016 | Dec 2024 |
IMP list
lock Showing 1 of 11 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bleomycin Sulfate | 1 | Unknown | 2016-07-15 | 2016-07-15 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.